| Anti-TNF user | Anti-TNF non-user | Increment (user vs non-user) | 95% CIa |
---|---|---|---|---|
Canada | ||||
 Costs | 12,405 | 1656 | 10,749 | (8868, 12,789) |
 QALYs | 0.626 | 0.609 | 0.017 | (−0.008, 0.042) |
 ICER |  |  | 626,459 | (247,149, Dominated) |
France | ||||
 Costs | 12,566 | 1696 | 10,870 | (9144, 12,751) |
 QALYs | 0.620 | 0.607 | 0.013 | (−0.011, 0.036) |
 ICER |  |  | 857,992 | (284,242, Dominated) |
UK | ||||
 Costs | 12,973 | 737 | 12,236 | (8981, 15,769) |
 QALYs | 0.627 | 0.606 | 0.021 | (−0.015, 0.059) |
 ICER |  |  | 578,899 | (187,442, Dominated) |
Germany | ||||
 Costs | 12,321 | 1682 | 10,640 | −877,112,728 |
 QALYs | 0.642 | 0.617 | 0.025 | (0.001, 0.050) |
 ICER |  |  | 422,568 | (206,749, 14,587,057) |
Hong Kong | ||||
 Costs | 11,935 | 891 | 11,044 | (7243, 15,470) |
 QALYs | 0.619 | 0.586 | 0.033 | (−0.011, 0.076) |
 ICER |  |  | 335,418 | (124,073, Dominated) |